Scarica l'app Stockscreener
68.91
9.92%
6.22
Dopo l'orario di chiusura:
69.34
0.43
+0.62%
Tempus Ai Inc Borsa (TEM) Ultime notizie
Why Tempus AI Inc. (TEM) Skyrocketed On Tuesday - Yahoo Finance
Tempus AI announces six posters accepted for presentation at ISPOR 2025 - TipRanks
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025 - FinancialContent
Is Tempus AI, Inc. (TEM) the Best Performing Healthcare Stock to Buy Now? - Yahoo Finance
Tradr Launches First Leveraged ETF on Tempus AI - PR Newswire
Biovica collaborates with Tempus to expand the commercial reach of DiviTum® TKa - TradingView
Tempus AI Reports Strong Growth and Strategic Partnerships in Earnings Call - MSN
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Jim Cramer Says Stay Away from This Nancy Pelosi Stock - MSN
These AI Stocks Posted Robust Results: Time to Buy? - The Globe and Mail
The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Tempus AI Stock: Time to Double Down or Cut and Run? - MSN
Morgan Stanley raises Tempus AI price target to $65 from $60 - Investing.com Australia
Tempus AI COO Ryan Fukushima Sells 20,000 Shares - TradingView
Tempus AI, Inc. Class A (TEM) Gets a Hold from Piper Sandler - The Globe and Mail
Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday - Insider Monkey
Why These 10 Stocks Soared Today - Insider Monkey
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals - Benzinga
Tempus AI price target raised to $65 from $60 at BTIG - TipRanks
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight - GlobeNewswire Inc.
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
What’s Next For Tempus AI Stock? - Forbes
Tempus AI, Inc. (TEM): Among Most Popular Stocks on Robinhood in 2025 - Insider Monkey
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures - Benzinga
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Tempus AI raises revenue guidance to $1.25B for 2025, supported by new $200M AstraZeneca deal - MSN
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Tempus: Q1 Earnings Snapshot - MySA
Earnings call transcript: Tempus AI Q1 2025: Revenue Surges, Stock Dips - Investing.com India
Tempus AI Inc Reports Q1 2025 Revenue of $255.7 Million and Net Loss of $68 Million - GuruFocus
On heels of big data deals, Tempus AI touts robust revenue - Crain's Chicago Business
Tempus AI beats Q1 expectations, raises 2025 outlook; shares dip 2.3% - Investing.com Nigeria
Tempus AI Q1 2025 slides: revenue surges 75%, approaching EBITDA profitability - Investing.com India
Tempus AI Q1 Non-GAAP Loss Narrows; Revenue Rises; Slightly Ups Full Year Guidance - marketscreener.com
Tempus AI reports Q1 adjusted EPS (24c), consensus (27c) - TipRanks
Earnings Flash (TEM) Tempus AI Reports Q1 Revenue $255.7M, vs. FactSet Est of $248.1M - marketscreener.com
Tempus Reports First Quarter 2025 Results - Bluefield Daily Telegraph
Tempus AI Stock Dips as Earnings on Deck (NASDAQ: TEM) – What To Expect - AskTraders.com
Tempus selects TIME Network for Phase I clinical trials - MSN
TEMPUS (Nasdaq: TEM) Earnings: Live Coverage And What to Expect - AOL.com
tempus AI Inc Class A call volume above normal and directionally bullish - TipRanks
Tempus AI (Nasdaq: TEM) Earnings: Live Coverage And What to Expect - 24/7 Wall St.
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. - AOL.com
Jim Cramer Warns on Tempus AI (TEM): “Diagnostics With no Dough? I’m Out” - Insider Monkey
0.34%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):